Our latest episode takes a slightly different format than usual. It's important to note that this episode is primarily opinion-based and should not be taken as fact. We hope you find it as entertaining as we did making it! We're joined by Lisa, a guest from the community who works in the pharmaceutical industry. Lisa bravely shares her personal journey with lifelong weight struggles and diet culture and discusses how GLP1s have helped her manage various health conditions such as PCOS, hypothyroidism, and obesity. Lisa then joins The Plus SideZ Crew to "speculate our faces off" on topics including:The state of the original and newest Mounjaro savings card, The impending FDA approval for the obesity indication for Mounjaro, Pharmacy Benefit Managers (PBMs) leveraging our community TikToks for intel as they crackdown on the off-label use of Mounjaro, Ozempic, and other GLP-1s,Pharmacy benefit managers (PBMs) conducting audits and withdrawing approved prior authorizations (PAs) for GLP-1 drugs,Emerging, wild TikTok trends in June claiming "GLP-1 dupes" driven by the original Mounjaro savings card ending, andThe benefits and dangers of some compound pharmacies providing GLP-1s like Semaglutide during and after the listed FDA shortage. Follow us on TikTok: Kim @dinosaurmonkeyfartsKimKat @KatCarter7Jernine @theejernineLisa  @lisag_ocAnd don't forget to subscribe and watch the show on YouTube @ThePlusSideZ Support the showKim Carlos @DMFKimonMounjaro on TikTokJernine Trott @TheeJernine on TikTokKat Carter @KatCarter7 on TikTokLydia Roberts @mounjaro_GLP_Help on TikTok